Florencio P S, Caulfield T
Faculty of Law, McGill University, Montreal, QC, Canada.
Can J Public Health. 1999 Jul-Aug;90(4):282-4. doi: 10.1007/BF03404132.
The debate over the acceptability of clinical trials for xenotransplantation has focussed primarily on analyses of: 1) the medical benefits that might accrue to individual patients in need of organ replacement therapy; 2) the risk of introducing new infectious disease(s) into the population; and 3) the ability of public safety measures to minimize that risk. It is now generally accepted that if we are to proceed with xenobiotechnology, sufficient public safety measures must first be adopted. Despite the growing consensus as to the indispensability of scientific safeguards, few authors have questioned the ability of current or novel legal frameworks to sustain and enforce such safeguards. A legal analysis of the public health concerns must be incorporated into the debate if we are to ensure a thorough and responsible decision-making process.
1）可能惠及需要器官替代治疗的个体患者的医疗益处；2）将新的传染病引入人群的风险；3）公共安全措施将该风险降至最低的能力。现在人们普遍认为，如果要推进异种生物技术，必须首先采取充分的公共安全措施。尽管对于科学保障措施的不可或缺性已达成越来越多的共识，但很少有作者质疑现行或新的法律框架维持和执行此类保障措施的能力。如果要确保进行全面且负责的决策过程，就必须将对公共卫生问题的法律分析纳入这场辩论。
